Yondelis and Decadron drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Yondelis (trabectedin) and Decadron (dexamethasone). Common drug interactions include blood creatine phosphokinase increased among females and platelet count decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Yondelis and Decadron. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Yondelis?

Yondelis has active ingredients of trabectedin. eHealthMe is studying from 1,220 Yondelis users. Check the latest studies of Yondelis.

What is Decadron?

Decadron has active ingredients of dexamethasone. It is often used in multiple myeloma. eHealthMe is studying from 47,210 Decadron users. Check the latest studies of Decadron.



On Jul, 12, 2026

17 people who take Yondelis and Decadron together, and have interactions are studied.

Yondelis and Decadron drug interactions.

What are the common drug interactions of Yondelis and Decadron, by gender? *:

female:

  1. Blood creatine phosphokinase increased
  2. Neutropenia (an abnormally low number of neutrophils)
  3. Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)
  4. Asthenia (weakness)
  5. Diarrhoea
  6. Febrile neutropenia (fever with reduced white blood cells)
  7. Sputum increased
  8. Abdominal discomfort
  9. Acute respiratory distress syndrome
  10. Alanine aminotransferase increased

male:

  1. Platelet count decreased
  2. Blood bilirubin increased
  3. Duodenal ulcer
  4. Gamma-glutamyltransferase increased
  5. Hypoalbuminaemia (levels of albumin in blood serum are abnormally low)
  6. Nausea (feeling of having an urge to vomit)
  7. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  8. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  9. Capillary leak syndrome (capillary leaks plasma)
  10. Cardiac failure

What are the common drug interactions of Yondelis and Decadron, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Neutropenia (an abnormally low number of neutrophils)
  2. Blood creatine phosphokinase increased
  3. Alanine aminotransferase increased
  4. Aspartate aminotransferase increased
  5. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  6. Capillary leak syndrome (capillary leaks plasma)
  7. Cardiac failure
  8. Febrile neutropenia (fever with reduced white blood cells)
  9. Full blood count decreased
  10. Pyrexia (fever)

50-59:

  1. Febrile neutropenia (fever with reduced white blood cells)
  2. Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)
  3. Sputum increased
  4. Asthenia (weakness)
  5. Gastrointestinal toxicity (damage to digestive tract by any substance)
  6. Haematotoxicity (toxins that destroy red blood cells)
  7. Urinary tract infection

60+:

  1. Platelet count decreased
  2. Blood bilirubin increased
  3. Gamma-glutamyltransferase increased
  4. Hypoalbuminaemia (levels of albumin in blood serum are abnormally low)
  5. Nausea (feeling of having an urge to vomit)
  6. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  7. Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)
  8. Asthenia (weakness)
  9. Dehydration (dryness resulting from the removal of water)
  10. Diarrhoea

What are the existing conditions these people have? *

  1. Nausea (feeling of having an urge to vomit): 3 people, 17.65%
  2. Liposarcoma (a cancer tumour that arises in fat cells in deep soft tissue): 3 people, 17.65%
  3. Leiomyosarcoma Metastatic (a very rare soft tissue sarcoma (cancer) that grows in muscle tissue spreading to other parts): 3 people, 17.65%
  4. Leiomyosarcoma (a very rare soft tissue sarcoma (cancer) that grows in muscle tissue): 2 people, 11.76%
  5. Synovial Sarcoma Metastatic (tumour of synovial membrane of joint spreads to other): 2 people, 11.76%
  6. Renal Impairment (severely reduced kidney function): 2 people, 11.76%
  7. Pain: 2 people, 11.76%
  8. Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 2 people, 11.76%
  9. High Blood Pressure: 2 people, 11.76%
  10. Uterine Leiomyosarcoma (uterus cancer of smooth muscle connective tissue): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Yondelis and Decadron?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Yondelis and Decadron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Yondelis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Decadron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Yondelis and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Decadron and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on trabectedin and dexamethasone (the active ingredients of Yondelis and Decadron, respectively), and Yondelis and Decadron (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: